348167-06-6

Upstream product

• 100-66-3 methoxybenzene 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 212688-02-3 3,5-dibromo-4-hydroxyphenylacetic acid methyl ester 

Downstream Products

• 348167-07-7 4-[3-(Cyclopentylacetyl)-4-hydroxyphenoxy]-3,5-dibromophenylacetic Acid Methyl Ester 
• 348167-17-9 4-[4-methoxy-3-nitrophenoxy]-3,5-dibromophenylacetic acid methyl ester 
• 64216-23-5 3,5-dibromo-4-(4-hydroxyphenoxy)phenylacetic acid 
• 725239-63-4 {3,5-dibromo-4-[4-hydroxy-3-(4-hydroxy-phenoxy)-phenoxy]-phenyl}-acetic acid 
• 725239-18-9 5-(2,6-dibromo-4-methoxycarbonylmethyl-phenoxy)-2-hydroxy-benzoic acid 

Relevant academic research and scientific papers

Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta

A set of thyromimetics having improved selectivity for TR-β1 were prepared by replacing the 3′-isopropyl group of 2 and 3 with substituents having increased steric bulk. From this limited SAR study, the most potent and selective compounds ident

THYROID RECEPTOR LIGANDS

Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at

NOVEL COMPOUNDS

This invention relates to novel compounds, which are thyroid receptor ligands, and to methods of preparing such compounds. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunctio

Compounds active at the glucocorticoid receptor

This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in therapy and in the regulation of metabolism, especially lowering blood glucose levels. The compounds referred to are compounds according to the formula (I).